ReviewClinical diabetes and endocrinology2024

Teplizumab's immunomodulatory effects on pancreatic β-cell function in type 1 diabetes mellitus.

Emmanuel Kokori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.